DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Fotemustine
Fotemustine
Bevacizumab Plus Fotemustine As First-Line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
Maintenance Therapy in Solid Tumors Marie-Anne Smit, MD, MS,1 and John L
An Analysis of Toxicity and Response Outcomes from Dose
Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver
II. Recurring Tumors
Neoplasia Treatment Compositions Containing Antineoplastic Agent and Side-Effect Reducing Protective Agent
Other Alkylating Agents
Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
Summary of Product Characteristics
Complete Response with Fotemustine and Bevacizumab After Early Progression Following Radiotherapy and Temozolomide Treatment in Patient with Glioblastoma Multiforme
EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood
Sorafenib Plus Daily Low-Dose Temozolomide for Relapsed Glioblastoma: a Phase II Study
GUIDE MANAGEMENT of HIGH GRADE GLIOMA Principles Of
1078-0432.CCR-10-2363.Full-Text.Pdf
Chemotherapy Drugs
Liste Des Molécules
Neoplasia Treatment Compositions Containing Antineoplastic Agent and Side-Effect Reducing Protective Agent
Top View
Bioflo Port Chemotherapy Testing Tech Note
Nber Working Paper Series the Impact of New Drug
Treatment of Metastatic Uveal Melanoma: Systematic Review
Unusual Serpentine Supravenous Hyperpigmentation During Chemotherapy Treatment
SFPO and ESOP Recommendations for The
EMETOGENICITY of CHEMOTHERAPY REGIMENS Version 2019
Antiemetic Regimens
DTIC), BCNU (Carmustine), Cisplatin and Tamoxifen (DBPT
FEAM) As a New Conditioning Regimen for Lymphoma Patients Undergoing Auto-SCT: a Multicenter Feasibility Study
Cytostatics in the Aquatic Environment: Analysis, Occurrence, and Possibilities for Removal
Monthly Literature Update October 2018
Fotemustine: a Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
BRAIN CANCER TREATMENT REGIMENS (Part 1 of 9) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
Australian PI – Tradename (Active Ingredient)
Chemotherapy Drugs
Viability of Microorganisms in Novel Chemical and Biopharmaceutical Anticancer Drug Solutions
Vitamin C): a New Frontier in the Treatment of Intraocular Cancer
Integrative Computational Approach Identifies Drug Targets in CD4+ T
Immunomedics®, Inc
Medical Oncology Services: Brain Cancer; Anaplastic Glioma, Systemic Recurrent Therapy
Melanoma Resistance to Photodynamic Therapy: New Insights
Central Nervous System Cancers Chemotherapy
(12) Patent Application Publication (10) Pub. No.: US 2016/0101219 A1 Jennings Et Al
Translesion Polymerase H Is Upregulated by Cancer Therapeutics and Confers Anticancer Drug Resistance
Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - Areview
Melanoma Resistance to Photodynamic Therapy: New Insights
Nanosystems for Improved Targeted Therapies in Melanoma
Fotemustine As Second-Line Treatment for Recurrent Or Progressive
Treatment of Metastatic Uveal Melanoma: Systematic Review
Enhancing the Efficiency of 5-Aminolevulinic Acid-Mediated
Antineoplastic Drugs
Hypoxia Promotes Synergy Between Mitomycin C and Bortezomib